ARS Pharmaceuticals (SPRY) Retained Earnings (2021 - 2026)
ARS Pharmaceuticals (SPRY) reported Retained Earnings of -$355.2 million for Q1 2026, down 191.99% on a YoY basis from $386.1 million in Q1 2025, and down 284276.8% sequentially from $125000.0 in Q4 2025.
ARS Pharmaceuticals (SPRY) Retained Earnings (2021 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 6 years of Retained Earnings data on file, last reported at -$355.2 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 191.99% year-over-year to -$355.2 million; the trailing twelve-month figure through Mar 2026 stood at -$355.2 million (down 191.99% YoY), and the FY2025 full-year result was $125000.0, down 99.97% from the prior year.
- Retained Earnings slipped to -$355.2 million in Q1 2026, from $125000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $510.6 million in Q2 2022 to a low of -$355.2 million in Q1 2026.
- A 5-year average of $150.0 million and a median of $407000.0 in 2022 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings soared 537513.24% in 2024 and slumped 191.99% in 2026, its largest moves.
- Tracing SPRY's Retained Earnings over 5 years: stood at $407000.0 in 2022, then soared by 88844.47% to $362.0 million in 2023, then increased by 4.94% to $379.9 million in 2024, then plunged by 99.97% to $125000.0 in 2025, then slumped by 284276.8% to -$355.2 million in 2026.
- Business Quant data shows SPRY's Retained Earnings at -$355.2 million in Q1 2026, $125000.0 in Q4 2025, and -$7000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | -355.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -355.22 Mn |
| Dec 31, 2025 | 125,000.00 |
| Sep 30, 2025 | -7,000.00 |
| Jun 30, 2025 | -202.13 Mn |
| Mar 31, 2025 | 386.14 Mn |
| Dec 31, 2024 | 379.87 Mn |
| Sep 30, 2024 | 373.87 Mn |
| Jun 30, 2024 | 369.49 Mn |
| Mar 31, 2024 | 365.58 Mn |
| Dec 31, 2023 | 362.00 Mn |
| Sep 30, 2023 | 361.57 Mn |
| Jun 30, 2023 | -180,000.00 |
| Mar 31, 2023 | 68,000.00 |
| Dec 31, 2022 | 407,000.00 |
| Sep 30, 2022 | -1.62 Mn |
| Jun 30, 2022 | 510.61 Mn |
| Mar 31, 2022 | -1.25 Mn |
| Dec 31, 2021 | 10.98 Mn |
| Sep 30, 2021 | -162.80 Mn |
| Jun 30, 2021 | -140.10 Mn |